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Introduction. X-linked agammaglobulinemia (XLA) is a primary immunodeficiency characterized by agammaglobulinemia
requiring replacement treatment with immunoglobulin. The association of XLA and membranoproliferative glomerulonephritis
(MPGN) is unexpected and, to our knowledge, only one case was previously published. Case Report. The authors report the case
of a 10-year-old boy with family history and prenatal diagnosis of XLA, treated from birth with intravenous immunoglobulin
replacement therapy. He presented with pneumonia, macroscopic hematuria, nephrotic proteinuria, hypoalbuminemia, and
hypercholesterolemia with normal renal function and serum complement levels. Renal histology showed immune complex
mediated MPGN. He was started on high dose prednisolone and ramipril and switched to weekly subcutaneous immunoglobulin.
After a 4-month treatment, hematuria and proteinuria significantly improved and prednisolone was gradually tapered without
relapse. Conclusion. The pathogenic process underlying MPGN development in this patient is unknown but residual humoral
immunity might play an important role. Thus, this case highlights the risk of autoimmune disorders among patients with
XLA.
1. Introduction
Membranoproliferative glomerulonephritis (MPGN) is an
uncommon cause of chronic nephritis that occurs primarily
in children and young adults. In most cases, complement
activation is prominent and immune complex formation and
deposition in the glomeruli play an important role [1–3]. On
the other hand, patients with X-linked agammaglobulinemia
(XLA, MIM number 300755), also known as Bruton agam-
maglobulinemia, have a profound defect in B-lymphocyte
development resulting in severe hypogammaglobulinemia.
Bruton tyrosine kinase (BTK) gene mutation on the X chro-
mosome has been identified as responsible for this disease.
Replacement therapy with regular administration of intra-
venous (IVIG) or subcutaneous (SCIG) immunoglobulin is
the only effective treatment, preventing severe infections,
which are the hallmark of the untreated disease [4].
The authors report the case of a patient with XLA who
developed MPGN during treatment with IVIG. The associa-
tion of XLA and MPGN is unusual and, to our knowledge,
only one case was previously reported [5], although other
cases with renal immune complex deposition were also
described [6] and are listed in Table 1.
2. Case Presentation
The patient in this report has a family history of XLA with
two affected siblings, with their mother being a carrier of
the mutation. He was screened prenatally and the genetic
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Table 1: Patients with XLA and renal disease due to immune complex deposition.
Reference Age Presentation Renal histology Treatment Outcome
Present case 10 years
Pneumonia,
macroscopic hematuria,
and nephrotic
proteinuria
MPGN type I
Switched
immunoglobulin brand;
corticosteroid therapy
Asymptomatic with normal
renal function and no
proteinuria and improved
hematuria
Yoshino et al., 2006
[5] 3 years
Microscopic hematuria,
nephrotic proteinuria,
and low serum
complement
MPGN type III
Switched
immunoglobulin brand;
corticosteroid therapy
Asymptomatic with normal
renal function and
improved hematuria and
proteinuria
Endo et al., 2011 [6] 23 years Microscopic hematuria Membranousglomerulopathy
Switched
immunoglobulin brand
Asymptomatic with normal
renal function and minimal
proteinuria
analysis revealed a BTK mutation (R288Q). A masculine
gender newborn was born after a full-term pregnancy with
a normal delivery, weighing 3250 grams, with an otherwise
unremarkable neonatal history. He was started on IVIG sho-
rtly after birth. He showed low but detectable levels of serum
IgG (1.85 g/L; reference range 7.24–1591), IgA (59mg/L; refe-
rence range 900–3320), and IgM (70mg/L; reference range
520–2080) with CD19+ 1.4% and CD 20+ 1.6% at the age of
8 months. Although the patient had a poor compliance with
medical follow-up, including IVIG treatment, there was no
record of major infections during childhood. At the age of
10 years, he was admitted with right lower lobe pneumonia
and macroscopic hematuria. Physical examination revealed
normal blood pressure and no peripheral edema. Initial
laboratory evaluation showed hypoalbuminemia (27 g/L; ref-
erence range 32–45), hypercholesterolemia (5.72mmol/L;
high >5.18) and normal renal function with serum cre-
atinine of 32.71 𝜇mol/L (reference range 46.9–69.8) and
estimated glomerular function rate of 2.62mL/s/m2. Urina-
lysis revealed proteinuria (urinary protein over creatinine
ratio of 632.8mg/mmol)with the following urinary sediment:
erythrocytes 50 per high power field (HPF), leucocytes 5–
10/HPF, and red blood cells and hialines casts 1-2/HPF.
Normal serum complement levels were observed, with C3
level of 1.51 g/L (reference range 0.81–1.67) and C4 of 0.32 g/L
(reference range 0.11–0.41).The etiological diagnosis of pneu-
monia could not be established.
Further investigation disclosed normal autoantibodies
serum levels and excluded HIVs 1 and 2, HBV, and HCV
infection, with negative viral load and normal liver enzy-
mes. A renal biopsy was performed and histology pre-
sented glomeruli with membranoproliferative patterns, with-
out significant interstitial inflammation or tubular atrophy
(Figure 1). Immunofluorescence study revealed glomerular
deposition of IgG (+++), C3 (++), C4 (+), C1q (++), and
traces of IgM in the mesangium and subendothelial space.
The patient was diagnosed with MPGN type I, reclassified as
immune complex mediated glomerulonephritis according to
a recent classification [3].
IVIG was switched to SCIG replacement therapy in a
weekly regimen and prednisolonewas also started at an initial
dose of 2mg/kg/day, which was gradually tapered. Rami-
pril was also started at a dose of 2,5mg/day. After 18
months the patient maintained a normal blood pressure
and normal renal function. The urinary sediment is near
normal (erythrocytes 5–10/HPF, leucocytes 0–2/HPF) and
no proteinuria was detected (urinary protein/creatinine ratio
of 20,34mg/mmol). There were no major infections and he
maintained an adequate growth (weight and stature z-scores
of 0.81 and 0.31 at age of 12 years).
3. Discussion
The classic XLA phenotype is characterized by a reduced
peripheral B-lymphocyte count and near complete absence
of endogenous immunoglobulin. More than 500 different
BTK mutations have been reported in patients with XLA
but a consistent correlation between genotype and phenotype
remains to be established [7]. Given this low level of immu-
noglobulin, XLA patients should not be prone to immune
complex mediated disorders. Even so, this patient had a
MPGN characterized by immune deposits in the mesangium
and subendothelial space, which is thought to reflect the
deposition of circulating immune complexes [1].
Immune complex-mediated MPGN is most commonly
secondary to viral infections (hepatites C and B) and less fre-
quently to a chronic bacterial disease (e.g., endocarditis,
shunt nephritis, and abscesses). Although the patient had a
poor compliance with immunoglobulin treatment, no impo-
rtant infections were noted until the age of 10 years. Autoim-
mune diseases like systemic lupus erythematosus (particu-
larly in the chronic phase of lupus nephritis) and, less often,
Sjo¨gren’s syndrome or rheumatoid arthritis are also asso-
ciated with MPGN. The patient had neither clinical mani-
festations nor autoantibodies compatible with thesemultisys-
temic disorders.Monoclonal gammopathy is another cause of
secondaryMPGN but is an extremely rare diagnosis in child-
hood and no laboratory findings support it. So, like reported
in another XLA patient with MPGN, the most frequent sec-
ondary causes of MPGN were excluded, but a viral etiology
is still to be suspected [1, 5]. The preparation of immu-
noglobulin was also replaced by a different brand and swi-
tched to subcutaneous administration, making it unlikely
for immune complexes to be formed through the reaction
of IVIG with an endogenous antigen; the most likely hypo-
thesis is that they were formed by the reaction between
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Figure 1: Histology of the patient renal biopsy. (a) Proliferation of mesangial and endothelial cells and expansion of the mesangial matrix
(hematoxylin and eosin stained section; original magnification ×400); (b) global endocapillary proliferation and a double contour appearance
of the glomerular basement membrane (periodic acid-Schiff stained section; original magnification ×400).
the patients endogenous residual IgG and an endogenous
antigen. Although we cannot ascertain the precise level of
innate immunoglobulin because IVIG was started shortly
after birth, this patient exhibits detectable levels of IgA and
IgM and a greater percentage of B-cells than most patients
with XLA, whichmight imply a higher production of endoge-
nous IgG. Besides, the improvement following corticosteroid
therapy also supports that residual humoral immunity might
be causally related to the development of MPGN. It remains
unclear whether an association between XLA and MPGN
(or other forms of renal immune disease) can be established
and the underlying pathophysiologicmechanisms are still not
fully understood. However, there is growing evidence that
patients with primary immunodeficienciesmay also be prone
to develop autoimmune disorders due to an imbalance in
immunoregulatory pathways [8].
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